Clinical Trials Logo

Pancreatic Cancer clinical trials

View clinical trials related to Pancreatic Cancer.

Filter by:

NCT ID: NCT02777463 Completed - Pancreatic Cancer Clinical Trials

The Prediction Using Diffusion MRI of the Response Evaluation in BRPC in NAT.

DIFFERENT
Start date: June 2016
Phase:
Study type: Observational [Patient Registry]

To investigate the correlation between pretreatment ADC value of diffusion MRI and pathologic response in patients with borderline resectable pancreatic carcinoma who undergo neoadjuvant therapy.

NCT ID: NCT02720666 Completed - Pancreatic Cancer Clinical Trials

K-001 Treatment of Advanced Pancreatic Cancer: Clinical Trial of Monotherapy's Tolerability

Start date: January 2016
Phase: Phase 1
Study type: Interventional

This study is an open and single-center Phase I clinical research on patients with advanced pancreatic cancer, for evaluating their adverse reactions or tolerance to K-001, so as to determine the safe and reasonable dosage and dosing regimen.

NCT ID: NCT02718859 Completed - Pancreatic Cancer Clinical Trials

Combination of Irreversible Electroporation and NK Immunotherapy for Advanced Pancreatic Cancer

Start date: March 1, 2016
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety and efficacy of the combined therapy using irreversible electroporation(IRE)and nature killer(NK) cells for advanced pancreatic cancer.

NCT ID: NCT02713529 Completed - Colorectal Cancer Clinical Trials

Safety and Efficacy Study of AMG 820 and Pembrolizumab Combination in Select Advanced Solid Tumor Cancer

Start date: April 14, 2016
Phase: Phase 1/Phase 2
Study type: Interventional

A multi-center Phase 1b/2 study testing the combination of AMG 820 and pembrolizumab in subjects with select advanced solid tumors.

NCT ID: NCT02704156 Completed - Pancreatic Cancer Clinical Trials

SBRT Plus Pembrolizumab and Trametinib for Pancreatic Cancer

Start date: October 2016
Phase: Phase 2
Study type: Interventional

Hypothesis: Survival benefits could be found in SBRT Plus Pembrolizumab and Trametinib compared with SBRT plus gemcitabine.

NCT ID: NCT02704143 Completed - Pancreatic Cancer Clinical Trials

Combination of SBRT With Sequential S-1 for Treating Locally Advanced Pancreatic Cancer

Start date: February 2016
Phase: N/A
Study type: Interventional

The safety and efficacy of combination of SBRT with sequential S-1 in treating patients with locally advanced pancreatic cancer and poor medical conditions will be evaluated.

NCT ID: NCT02702986 Completed - Pancreatic Cancer Clinical Trials

Safety and Feasibility of imILT Locally Advanced Pancreatic Cancer (LAPC)

Start date: February 2016
Phase: Phase 1
Study type: Interventional

10 Patients with Locally Advanced Pancreatic Cancer, no further responsive to neoadjuvant treatments but with a Stage-III disease will be submitted to imILT (Immunostimulating Interstitial Laser Thermotherapy). Safety and feasibility of imILT on LAPC will be evaluated as primary objective. Secondary objectives will be QoL after imILT, study of the immune reaction after imILT, oncological analysis of patients suffering from LAPC submitted to imILT.

NCT ID: NCT02695966 Completed - Pancreatic Cancer Clinical Trials

EVIS - Ex-vivo Assessment of T-lymphocyte Homing in Primary Pancreatic Cancer

EVIS
Start date: May 2015
Phase:
Study type: Observational

This is a single-centre, prospective, non-randomised research study. The research team will investigate the feasibility of assessing primary human pancreatic tissue for changes to T lymphocyte function and localisation in the presence and absence of AMD3100.

NCT ID: NCT02694536 Completed - Pancreatic Cancer Clinical Trials

A Study of Erlotinib in Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer

Start date: June 2006
Phase: Phase 3
Study type: Interventional

This open-label, single-arm, multicenter trial is designed to evaluate the safety of erlotinib in combination with standard of care chemotherapy (gemcitabine) in participants with locally advanced, unresectable, or metastatic pancreatic cancer.

NCT ID: NCT02681796 Completed - Pancreatic Cancer Clinical Trials

Epidural Analgesia Use in Pancreatic Resections

E-PRO I
Start date: June 7, 2016
Phase: Phase 1
Study type: Interventional

The rationale for this study is to investigate the benefits of epidural analgesia in pancreatic resections in a prospective, single blind, randomized control trial. This study will evaluate both short and long-term outcomes related to epidural analgesia, providing a longitudinal and comprehensive perspective to the advantages and disadvantages of this technique. The investigators hypothesize that the use of epidural analgesia reduces a patient's consumption of morphine or morphine-equivalent in the post-operative period following pancreatic resections.